


Fig. 5S



**Fig.5S.** Icaritin treatment induced clinical activity and dynamic biomarkers. HCC patients include patients of PR (01A04), SD (01A07, 01A08) and PD (01A05, 01A06). Methods: For DKK1, a commercial ELISA kit (R&D Systems, Minneapolis, MN, USA) was used according to the method of Shen et al. (The Lancet Oncology. 2012;13(8):817-26). The changes in cytokines such as IFN- $\gamma$ , IL-2, IL-6, IL-8, IL-10, TNF- $\alpha$ , GM-CSF, IL-7, IL-15, and IL-17A were measured

---

with a customized platform on a Sector Imager 6000 instrument (MSD, Gaithersburg, MD, USA).